Neoplasms in the brain are uncommon in control Fischer 344 (F344) rats; they occur at a rate of less than 1% in 2-yr toxicity/ carcinogenicity studies. Furthermore, only 10 of nearly 500 studies conducted by the National Toxicology Program (NTP) showed any evidence of chemically related neoplastic effects in the brain. Generally, the brain tumor responses were considered equivocal, because the characteristics of potential neurocarcinogenic agents (such as statistically significant increased incidences, decreased latency and/or survival, and demonstration of dose-response relationships) were not observed. A thorough examination, including comparisons with a well-established historical database, is often critical in evaluating rare brain tumors. Chemicals that gave equivocal evidence of brain tumor responses were generally associated with carcinogenicity at other sites, and many chemicals were mutagenic when incubated with metabolic activating enzymes. Other factors that were supportive of the theory that marginal increases in brain tumor incidence were related to chemical exposure were that (a) some of the tumors were malignant, (b).no brain neoplasms were observed in concurrent controls from some studies, and/or (c) brain tumors were also seen following exposure to structurally related chemicals. In 2-yr studies in F344 rats (studies conducted by the NTP), equivocal evidence of carcinogenicity was observed for the following 9 chemicals: isoprene, bromoethane, chloroethane, 3,3'-dimethylbenzidine dihydrochloride, 3,3'-dimethoxybenzidine dihydrochloride, furosemide, C.I. direct blue 15, diphenhydramine hydrochloride, and 1-H-benzotriazole. Glycidol was the only chemical evaluated by the NTP with which there was clear evidence of brain tumor induction in F344 rats. Clarification of the potential neurocarcinogenic risks of chemicals that produce equivocal evidence of a brain tumor response in conventional 2-yr rodent studies may be aided by the use of transgenic mouse models that exhibit genetic alterations that reflect those present in human brain tumors as well as by the use of in utero exposures.
Bigner DD, Bigner SH, Burger PC, and Shelburne JD (1986). Primary brain tumors in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water. Food Chem. Toxicol.24: 129-137.
2.
Boorman GA and Eustis SL (1986). The pathology working group as a means for assuring pathology quality in toxicological studies. In: Managing Conduct and Data Quality of Toxicologic Studies, BK Hoover, JK Baldwin, AF Uelner, CE Whitmire, CL Davis, and DW Bristol (eds). Princeton Scientific Publishing, Princeton, New Jersey, pp. 271-275.
3.
Druckrey H., Perussmann R., Ivankovic S., and Schmahl D. (1967). Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen in BD-Ratten. Z. Krebsforsch69: 103.
4.
Druckrey H., Schagen B., and Ivankovic S. (1970). Malignome durch einmalige Gabe von Athylnitrosoharnstoff (ANH) an neugeborene und junge BD IX-Ratten. Z. Krebsforsch74: 141-161.
5.
Ekstrand AJ, Longo N., Hamid ML, Olson JJ, Liu L., Collins VP, and James CD (1994). Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene9: 2313-2320.
6.
Garman RH, Snellings WM, and Maronpot RR (1985). Brain tumors in F344 rats associated with chronic inhalation exposure to ethylene oxide. Neurotoxicology6: 117-138.
7.
Garman RH, Snellings WM, and Maronpot RR (1986). Frequency, size and location of brain tumours in F-344 rats chronically exposed to ethylene oxide. Food Chem. Toxicol.24: 145-153.
8.
Hardisty JF and Boorman GA (1986). National Toxicology Program pathology quality assurance procedures. In: Managing Conduct and Data Quality of Toxicologic Studies, BK Hoover, JK Baldwin, AF Uelner, CE Whitmire, CL Davis, and DW Bristol (eds). Princeton Scientific Publishing, Princeton, New Jersey, pp. 263-269.
9.
Haseman JK, Arnold J., and Eustis SL (1990). Tumor incidences in Fischer 344 rats: NTP historical data. In: Pathology of the Fischer Rat, GA Boorman, SL Eustis, MR Elwell, C Montgomery, and WF MacKenzie (eds). Academic Press, Inc., San Diego, pp. 555-564.
10.
Haseman JK, Hailey JR, and Morris RW (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol. Pathol.26: 428-441.
11.
Holly EA, Bracci PM, Mueller BA, and Preston-Martin S. (1998). Farm and animal exposures and pediatric brain tumors: Results from the United States West Coast childhood brain tumor study. Cancer Epidemiol. Biomarkers Prev.7: 797-802.
12.
Jeffrey JH, Olson J., and James CD (1995). Lack of p16 INK4 or retinoblastoma protein (pRB), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res.55: 4833-4836.
13.
Kleihues P. (1997). Genetic pathways in the evolution of tumors of the nervous system. CIIT Activities17: 8-11.
14.
Kleihues P. , Aguzzi A., and Wiestler OD (1990). Cellular and molecular aspects of neurocarcinogenesis. Toxicol. Pathol.18: 193-203.
15.
Kleihues P. and Ohgaki H. (1998). Genetics of glioma progression and the definition of primary and secondary glioblastomas . Brain Pathol.7: 1131-1136.
16.
Koestner A. (1986). The brain-tumour issue in long-term toxicity studies in rats. Food Chem. Toxicol.24: 139-143.
17.
Koestner A. and Norton S. (1998). Nervous system. In: Fundamentals in Toxicologic Pathology, WM Haschek and CG Rousseaux (eds). Academic Press, San Diego, pp. 355-393.
18.
Koestner A. , Swenberg JA, and Wechsler W. (1971). Transplacental production with ethylnitrosourea of neoplasms of the nervous system in Sprague-Dawley rats. Am. J. Pathol.63: 37-50.
19.
Krinke G., Naylor DC, Schmid S., Frohlich E., and Schnider K. (1985). The incidence of naturally-occurring primary brain tumours in the laboratory rat. J. Comp. Pathol.95: 175-192.
20.
Lantos PL (1986). Development of nitrosourea-induced brain tumours—With a special note on changes occurring during latency. Food Chem. Toxicol.24: 121-127.
21.
Lantos PL, VandenBerg SR, and Kleihues P. (1996). Tumours of the nervous system. In: Greenfield's Neuropathology 9, DI Graham and PL Lantos (eds). Arnold , London, pp. 583-879.
22.
Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang SI, Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner SH, Giovanella BC, Ittmann M., Tycko B., Hibshoosh H., Wigler MH, and Parsons R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science275: 1943-1947.
23.
Lynch DW, Lewis TR, Moorman WJ, Burg JR, Groth DH, Khan A., Ackerman LJ, and Cockrell BY (1984). Carcinogenic and toxicologic effects of inhaled ethylene oxide and propylene oxide in F344 rats. Toxicol. Appl. Pharmacol.76: 69-84.
24.
Maltoni C., Ciliberti A., and Carretti D. (1982). Experimental contributions in identifying brain potential carcinogens in the petrochemical industry. Ann. NY Acad. Sci.381: 216-249.
25.
Melnick RL and Huff J. (1992). 1,3-butadiene: Toxicity and carcinogenicity in laboratory animals and in humans. Rev. Environ. Contam. Toxicol.124: 111-144.
26.
National Institutes of Health ( 1997). SEER Cancer Statistics Review, 1973-1994. NIH Publication No. 97-2789, Bethesda, Maryland.
27.
National Toxicology Program ( 1978). Bioassay of 1-H-Benzotriazole for Possible Carcinogenicity. Technical Report Series No. 88, CAS No. 95-14-7, National Institutes of Health, Bethesda, Maryland.
28.
National Toxicology Program ( 1989). Toxicology and Carcinogenesis Studies of Bromoethane (Ethyl Bromide) in F344/N Rats and B6C3F1 Mice (Inhalation Studies), CAS No. 74-96-4. Technical Report Series No. 363, pp. 1-186. National Institutes of Health, Research Triangle Park, North Carolina.
29.
National Toxicology Program ( 1989). Toxicology and Carcinogenesis Studies of Chloroethane (Ethyl Chloride) in F344/N Rats and B6C3F1 Mice (Inhalation Studies), CAS No. 75-00-3. Technical Report Series No. 346, pp. 1-161. National Institutes of Health, Research Triangle Park, North Carolina.
30.
National Toxicology Program ( 1989). Toxicology and Carcinogenesis Studies of Diphenhydramine Hydrochloride in F344/N Rats and B6C3F1 Mice (Feed Studies), CAS No. 147-24-0. Technical Report Series No. 355, pp. 1-176. National Institutes of Health, Research Triangle Park, North Carolina.
31.
National Toxicology Program ( 1989). Toxicology and Carcinogenesis Studies of Furosemide in F344/N Rats and B6C3F1 Mice (Feed Studies), CAS No. 54-31-9. Technical Report Series No. 356, pp. 1-190. National Institutes of Health, Research Triangle Park, North Carolina.
32.
National Toxicology Program ( 1990). Toxicology and Carcinogenesis Studies of 3,3'-Dimethoxybenzidine Dihydrochloride in F344/ N Rats (Drinking Water Studies), CAS No. 20325-40-0. Technical Report Series No. 372, pp. 1-201. National Institutes of Health, Research Triangle Park, North Carolina.
33.
National Toxicology Program ( 1990). Toxicology and Carcinogenesis Studies of 3,3'-Dimethylbenzidifze Dihydrochloride in F344/N Rats (Drinking Water Studies), CAS No. 612-82-8. Technical Report Series No. 390, pp. 1-239. National Institutes of Health, Research Triangle Park, North Carolina.
34.
National Toxicology Program (1990). Toxicology and Carcinogenesis Studies of Glycidol in F344/N Rats and B6C3F1 Mice, CAS No. 556-52-5. Technical Report Series No. 374, pp. 1-229. National Institutes of Health, Research Triangle Park, North Carolina.
35.
National Toxicology Program (1992). Toxicology and Carcinogenesis Studies of C.I. Direct Blue 15 in F344/N Rats (Drinking Water Studies), CAS No. 2429-74-5. Technical Report Series No. 397 , pp. 1-249. National Institutes of Health, Research Triangle Park, North Carolina.
36.
National Toxicology Program (1993). Toxicology and Carcinogenesis Studies of 1,3-Butadiene in B6C3F1 Mice (Inhalation Studies), CAS No. 106-99-0. Technical Report Series No. 434, pp. 1-391. National Institutes of Health, Research Triangle Park, North Carolina.
37.
National Toxicology Program ( 1997). Toxicology and Carcinogenesis Studies of Isoprene in F344/N Rats (Inhalation Studies), CAS No. 78-79-5. Technical Report Series No. 486, pp. 1-191. National Institutes of Health, Research Triangle Park, North Carolina.
38.
Oda H., Zhang S., Tsurutani N., Shimizu S., Nakatsuru Y., Aizawa S., and Ishikawa T. (1997). Loss of p53 is an early event in induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res.57: 646-650.
39.
Ohgaki H., Schauble B., zur Hausen A., von Ammon K., and Kleihues P. (1995). Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch.427: 113-118.
40.
Rasheed Bka , McLendon RE, Herndon JE, Friedman HS, Fiedmam AH, Bigner DD, and Bigner SH (1994). Alterations of the TP53 gene in human gliomas. Cancer Res.54: 1324-1330.
41.
Rice JM and Ward JM (1982). Age dependence of susceptibility to carcinogenesis in the nervous system. Ann. NY Acad. Sci.: 274-289.
42.
Smith MA, Freidlin B., Ries Lag, and Simon R. (1998). Trends in reported incidence of primary malignant brain tumors in children in the United States. J. Natl. Cancer Inst.90: 1269-1277.
43.
Solleveld HA , Bigner DD, Averill DR, Bigner SH, Boorman GA, Burger PC, Gillespie Y., Hubbard GB, Laerum OD, McComb RD, McGrath JT, Morgan KT, Peters A., Rubinstein LJ, Schoenberg BS. Schold SC, Swenberg JA, Thompson MB. Vandevelde M., and Vinores SA (1986). Brain tumors in man and animals: Report of a workshop . Environ. Health Perspect.68: 155-173.
44.
Solleveld HA and Boorman GA (1990). Brain. In: Pathology of the Fischer Rat, GA Boorman, SL Eustis, MR Elwell, CA Montgomery, and WF MacKenzie (eds). Academic Press, Inc., San Diego, pp. 155-177.
45.
Swenberg JA (1982). Current approaches to the experimental investigation of chemicals in relation to cancer of the brain . Ann. NY Acad. Sci.381: 43-49.
46.
Takahashi JA , Mori H., Fukumoto M., Igarashi K., Jaye M., Oda Y., Kikuchi H., and Hatanaka M. (1990). Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues . Proc. Natl. Acad. Sci. USA87: 5710-5714.
47.
Walker VE and Swenberg J. (1988). Gliomas, Rat. In: Nervous System: Monographs on Pathology of Laboratory Animals, TC Jones, U Mohr, and RD Hunt (eds). Springer-Verlag, New York, pp. 134-143.
48.
Ward JM and Rice JM (1982). Naturally occurring and chemically induced brain tumors of rats and mice in carcinogenesis bioassays. Ann. NY Acad. Sci.381: 304-319.
49.
Watanabe K. , Sato K., Biernat W., Tachibana O., von Ammon K., Ogata N., Yonekawa Y., Kleihues P., and Ohgaki H. (1997). Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res.3: 523-530.
50.
Wechsler W. , Kleihues P., Matsumoto D., Zulch KJ, Ivankovic S., Preussmann R., and Druckrey H. (1969). Pathology of experimental neurogenic tumors chemically induced during prenatal and postnatal life. Ann. NY Acad. Sci.159: 360-408.
